Boston Scientific and Pain Alliance Europe now partner against chronic pain
Jan 21, 2015
Pain Alliance Europe (PAE) and Boston Scientific will start as of today a meaningful cooperation which will help both entities advance their mission. The terms of the partnership were concluded in a meeting between PAE and Boston Scientific which took place at the PAE office, in Brussels on the 9th of January.
The Boston Scientific grant to PAE will help sustain some of its core activities in 2015 and meaningfully advance its mission and goals: to promote awareness for chronic pain, to promote a European policy on chronic pain and to reduce the impact of chronic pain on the European society on all areas. The voice of chronic pain patients needs to be heard by all stakeholders involved in the battle to reduce the personal, societal and economic impact of this condition.
"This collaboration can be seen as a further acknowledgement that PAE is becoming an important and reliable stakeholder. Collaborations like this help us to come closer to our mission: to improve the quality of life of people living with chronic pain.” – Joop van Griensven, president PAE.
“Our partnership with PAE organization is an important step towards our commitment to increase awareness of chronic pain and our mission to transforming lives through innovative medical solutions. We believe our collaboration with PAE will help bring awareness to the impact of chronic pain on sufferers and societies, and will contribute to improve optimal pain management across Europe” - Vincent Sourdaine, director Neuromodulation Europe.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.
About Boston Scientific Neuromodulation
Boston Scientific’s Neuromodulation division was created in 2004. We are dedicated to advancing Spinal Cord Stimulation (SCS) and Deep Brain Stimulation (DBS) and partnering with the community of chronic pain and movement disorder specialists who deliver these life-changing technologies to patients. Our implantable neuromodulation devices treat neurological conditions through the delivery of focused electrical current to targeted nerve fibres. In 2004, we introduced the industry's first rechargeable battery (Precision™ Spinal Cord Stimulation System), allowing longer life than non-rechargeable systems and requiring fewer replacement surgeries.
About Spinal Cord Stimulation
Spinal Cord Stimulation, or SCS sends electrical impulses that stimulate nerve fibres along the spinal cord, masking the pain message traveling to the brain. Instead the patient will feel a tingling sensation known as paraesthesia. Watch this animation to learn more CLICK HERE
About Pain Alliance Europe
For Pain Alliance Europe (PAE), quality of life for a chronic pain patient means giving the patient the right to choose the best possible solutions and support to live his life according to his possibilities and wishes. The organization aims to promote awareness for chronic pain, to European society on all areas. PAE has as members 30 national European patient organisations which support and represent patients suffering from pain from over 15 European countries ( Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Italy, Ireland, The Netherlands, Poland, Romania, Spain, Sweden, United Kingdom).
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, technology and product pipeline, markets for our products and our position in those markets, new product launches and launch cadence, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.